Skip to main content

Table 2 Pneumococcal serotype-specific IgG GMC (95% confidence interval [CI]) in μg/mL before vaccination, post-PCV and post-PPV23 in treatment groups and controls

From: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

 

Rituximab (n = 30)

Abatacept (n = 23)

cDMARD (n = 27)

Controls (n = 28)

Serotype

Pre-PCV

Post-PCV

Post-PPV23

Pre-PCV13

Post-PCV13

Post-PPV23

Pre-PCV13

Post-PCV13

Post-PPV23

Pre-PCV13

Post-PCV13

Post-PPV23

1

–

–

–

0.11 (0.06–0.21)

0.37 (0.19–0.73)

0.40 (0.22–0.73)

0.10 (0.05–0.18)

0.27 (0.12–0.62)

0.84 (0.40–1.77)

0.12 (0.08–0.16)

1.09 (0.58–2.03)

3.21 (1.80–5.75)

3

–

–

–

0.10 (0.05–0.19)

0.35 (0.12–1.01)

0.38 (0.15–0.98)

0.06 (0.03–0.11)

0.14 (0.07–0.25)

0.21 (0.10–0.45)

0.08 (0.04–0.16)

0.68 (0.33–1.40)

1.90 (0.83–4.36)

4

0.13 (0.07–0.23)

0.17 (0.10–0.29)

0.12 (0.07–0.21)

0.13 (0.07–0.24)

0.28 (0.14–0.58)

0.29 (0.14–0.60)

0.11 (0.07–0.17)

0.36 (0.19–0.69)

0.77 (0.29–2.02)

0.18 (0.12–0.28)

2.15 (1.09–4.26)

4.07 (1.93–8.56)

5

–

–

–

0.17 (0.07–0.43)

0.48 (0.20–1.14)

0.53 (0.23–1.24)

0.11 (0.07–0.17)

0.54 (0.23–1-27)

0.89 (0.39–2.08)

0.09 (0.06–0.13)

0.61 (0.36–1.03)

1.52 (0.77–3.00)

6B

0.16 (0.09–0.29)

0.22 (0.11–0.42)

0.17 (0.08–0.34)

0.20 (0.10–0.39)

0.77 (0.33–1.79)

0.76 (0.33–1.77)

0.17 (0.08–0.38)

0.62 (0.27–1.43)

0.67 (0.28–1.65)

0.16 (0.07–0.33)

1.32 (0.56–3.14)

2.41 (1.02–5.69)

7F

–

–

–

0.31 (0.20–0.46)

1.80 (0.90–3.60)

1.89 (0.95–3.74)

0.51 (0.29–0.91)

2.57 (1.31–5,05)

2.42 (1.25–4.68)

0.23 (0.12–0.46)

3.48 (2.02–6.02)

4.04 (2.03–8.05)

9V

0.15 (0.08–0.25)

0.17 (0.10–0.30)

0.14 (0.08–0.24)

0.22 (0.11–0.45)

0.93 (0.45–1.91)

0.92 (0.44–1.96)

0.12 (0.07–0.23)

0.58 (0.26–1.26)

0.58 (0.32–1.07)

0.15 (0.09–0.25)

1.60 (0.87–2.94)

1.94 (1.09–3.47)

14

3.15 (1.70–5.82)

3.93 (2.22–6.96)

3.24 (1.84–5.79)

1.60 (0.70–3.71)

5.89 (3.10–11.18)

6.44 (3.61–11.49)

0.54 (0.26–1.11)

2.89 (1.31–6.33)

3.28 (1.66–6.46)

1.10 (0.50–2.43)

6.77 (3.50–13.12)

13.07 (9.36–18.26)

18C

0.69 (0.43–1.10)

0.83 (0.53–1.31)

0.60 (0.36–1.00)

0.76 (0.35–1.63)

3.90 (1.97–7.72)

4.21 (2.32–7.63)

0.41 (0.24–0.71)

2.83 (1.76–4.56)

2.37 (1.42–3.95)

1.03 (0.59–1.81)

5.74 (3.91–8.41)

6.33 (4,07–9.82)

19A

–

–

–

0.31 (0.12–0.80)

1.01 (0.37–2.76)

1.05 (0.37–3.02)

0.20 (0.09–0.43)

0.86 (0.33–2.29)

0.71 (0.27–1.88)

0.20 (0.08–0.47)

1.40 (0.60–3.29)

2.19 (0.94–5.07)

19F

0.84 (0.51–1.39)

0.96 (0.58–1.60)

0.64 (0.38–1.09)

0.76 (0.39–1.46)

1.25 (0.68–2.33)

1.53 (0.74–3.14)

0.85 (0.46–1.60)

1.89 (0.83–4.32)

4.38 (1.76–10.93

0.78 (0.48–1.25)

3.09 (1.59–6.03)

12.52 (5.35–29.30)

23F

0.32 (0.20–0.53)

0.41 (0.26–0.66)

0.34 (0.21–0.55)

0.70 (0.40–1.23)

3.10 (1.50–6.36)

2.83 (1.35–5.93)

0.34 (0.19–0.62)

1.17 (0.50–2.74)

1.46 (0.73–2.94)

0.41 (0.23–0.71)

6.12 (3.23–11.61)

6.30 (3.25–12.21)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us